S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Pharmacyclics Receives 2014 Society for Medicines Research Award for Drug Discovery for Ibrutinib (IMBRUVICA®)|
|AstraZeneca And Pharmacyclics Enter Clinical Trial Collaboration To Evaluate IMBRUVICA® In Hematologic Cancers|
|AstraZeneca And Pharmacyclics Enter Immuno-Oncology Clinical Trial Collaboration With IMBRUVICA® In Solid Tumors|
|Pharmacyclics Announces Launch of informCLL™ Registry for Chronic Lymphocytic Leukemia (CLL) Patients|
|Pharmacyclics Announces Update on IMBRUVICA® (ibrutinib) Waldenstrom's macroglobulinemia (WM) Submission|
|Pharmacyclics Announces Conference Call to Discuss Third Quarter Financial Results|
|Pharmacyclics Named 2014 Outstanding Company by BayBio|
|Pharmacyclics Announces Preliminary 2014 U.S. Net Product Revenue Results and 2015 U.S. Net Product Revenue Outlook|
|IMBRUVICA® (ibrutinib) Data Suggests Promise in Multiple Myeloma (2014/12/6)|
|IMBRUVICA® (ibrutinib) in Combination with Rituximab Data Shows Positive Benefit-Risk Profile in Hematologic Malignancy (2014/12/9)|
Click above to view more mutual fund data and stats for pcyc - Pharmacyclics Inc.